EUDA Health Holdings Limited (NASDAQ: EUDA) inks tri-party MOU on iPSC cell therapies
Rhea-AI Filing Summary
EUDA Health Holdings Limited entered into a tri-party Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. to collaborate on next-generation therapies derived from induced pluripotent stem cells, including NK-TCR cell therapies.
The company states this collaboration is a significant milestone that aligns with its strategy to strengthen commercialization and distribution of innovative, science-backed wellness and non-invasive healthcare products and services. EUDA focuses on Singapore, Malaysia and China and aims to serve over 1.8 billion people in a region where more than 30% of the population is rapidly aging, with an emphasis on the longevity sector.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Memorandum of Understanding regulatory
induced pluripotent stem cells medical
NK-TCR cell therapies medical
non-invasive healthcare medical
longevity sector medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did EUDA (EUDA) announce on July 28, 2026?
Who are the partners in EUDA Health’s new tri-party MOU (EUDA)?
What technologies are covered by EUDA’s latest collaboration (EUDA)?
Which markets does EUDA Health (EUDA) primarily focus on?
What long-term mission does EUDA Health (EUDA) describe?
Does EUDA Health’s press release (EUDA) include forward-looking statements?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-40678
EUDA Health Holdings Limited
(Exact Name of Registrant as Specified in its Charter)
60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: +65 6327 1110
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Other Events.
On July 28, 2026, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.
Exhibits
| 99.1 | Press release dated July, 28 2026. |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Dated: July 28, 2026 | ||
| EUDA Health Holdings Limited | ||
| By: | /s/ Alfred Lim | |
| Name: | Alfred Lim | |
| Title: | Chief Executive Officer | |
| 3 |
Exhibit 99.1
EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies
SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding (“MOU”) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”) to establish a tri-party collaboration with next-generation therapies derived from induced pluripotent stem cells (“iPSC”).
| ● | The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization of a first of its kind next generation of off-the-shelf oncology cell therapies for cancer treatment applications and wellness |
Alfred Lim, Chief Executive officer of EUDA commented: “This collaborative agreement represents a significant milestone for our company. The agreement aligns with our strategy to strengthen commercialization and distribution capabilities in innovative, science-backed wellness and non-invasive healthcare products and services. We anticipate the market will be robust for our next generation therapies as we demonstrate the effectiveness of our top of the line suite of product offerings. Our products represent a dramatic improvement over the current products available today. We intend to reach our goal of increasing value for shareholders as we successfully launch this product in the market”.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China. The Company aims to become a market leading distributor of non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By facilitating access to innovative, accessible, and science-backed third-party wellness and non-invasive healthcare products and services, EUDA is positioned to help with the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking Statements
Certain statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that refer to expectations or other characterizations of future events, circumstances or results are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The factors may include, but not be limited to, factors related to the Company’s anticipated growth strategies, future business development, ability to launch new products, enter into distribution agreements or strategic alliances with third parties, expand to other related industries or markets, and other information contained in the Company’s annual reports on Form 20-F, and detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission. The views expressed are those of management and are based on currently available information. Estimates and projections contained herein have been prepared by management and involve significant elements of subjective judgment and analysis and are based on certain assumptions. No representation nor warranty, expressed or implied, is made as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be relied upon, as a promise or representation, whether as to the past or the future. You are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.
This press release is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company’s stock. This press release is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice.
Christensen Advisory
Christian Arnell
Phone: +852 2117 0861
Email: christian.arnell@christensencomms.com